December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Subcutaneous administration of teclistamab (JNJ-64007957) was well tolerated and associated with high response rates at the RP2D in an ongoing phase I trial of heavily pretreated patients with multiple myeloma.